◆ NeutralUNCYALHCJEF
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
GlobeNewswire Inc.·
Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations related to false or misleading statements about FDA review of its OLC New Drug Application. The company received a second Complete Response Letter on June 30, 2026, citing manufacturing deficiencies, which led to a stock price decline. Investors who have suffered losses are encouraged to contact the firm.
Read Full Article at GlobeNewswire Inc. →